1. 1. Li H, Qin S, Liu Y, et al. (2021) Camrelizumab combined with FOLFOX4 regimen as first-line therapy for advanced hepatocellular carcinomas: a sub-cohort of a multicenter phase Ib/II study. Drug Design, Development and Therapy, 15: 1873-1882. [
DOI:10.2147/DDDT.S304857]
2. Chen W, Mao Y, Liu C, et al. (2021) Exosome in Hepatocellular Carcinoma: an update. Journal of Cancer, 12: 2526-2536. [
DOI:10.7150/jca.54566]
3. Nakharutai N, Chitapanarux I, Traisathit P, et al. (2023) Prediction of survival and analysis of prognostic factors for hepatocellular carcinoma: a 20-year of imaging diagnosis in Upper Northern Thailand. BMC cancer, 23: 1063. [
DOI:10.1186/s12885-023-11429-6]
4. Papadakos SP, Machairas N, Stergiou IE, et al. (2023) Unveiling the Yin-Yang balance of M1 and M2 macrophages in hepatocellular carcinoma: role of exosomes in tumor microenvironment and immune modulation. Cells, 12(16): 2036. [
DOI:10.3390/cells12162036]
5. Jia W, Han Y, Mao X, et al. (2022) Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Advances, 12: 31068-31082. [
DOI:10.1039/D2RA05127C]
6. Liu C, Fan H, Guan L, et al. (2021) In vivo and in vitro efficacy of crocin against Echinococcus multilocularis. Parasites & Vectors, 14: 364. [
DOI:10.1186/s13071-021-04866-4]
7. Xin X, Cheng X, Zeng F, et al. (2024) The role of TGF-β/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int J Biol Sci, 20: 1436-1451. [
DOI:10.7150/ijbs.89568]
8. White DL, Thrift AP, Kanwal F, et al. (2017) Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology, 152: 812-820.e815. [
DOI:10.1053/j.gastro.2016.11.020]
9. Yang L, Yan C, Wang J (2022) Effect of multi-disciplinary team care program on quality of life, anxiety, and depression in hepatocellular carcinoma patients after surgery: A randomized, controlled study. Frontiers in Surgery, 9: 1045003. [
DOI:10.3389/fsurg.2022.1045003]
10. Zeng S, Wang Z, Zhu Q, et al. (2023) Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study. Translational Cancer Research, 12: 93-112. [
DOI:10.21037/tcr-22-1912]
11. Hatooka M, Kawaoka T, Aikata H, et al. (2018) Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer, 18: 633. [
DOI:10.1186/s12885-018-4519-y]
12. Yao M, Ma M, Xu H, et al. (2018) Small PLGA nanocapsules Co-encapsulating copper sulfide nanodots and fluorocarbon compound for photoacoustic imaging-guided HIFU synergistic therapy. RSC Advances, 8: 4514-4524. [
DOI:10.1039/C7RA12074E]
13. Hui TC, Kwan J, Pua U (2021) Advanced techniques in the percutaneous ablation of liver tumors. Diagnostics (Basel), 11(4): 585. [
DOI:10.3390/diagnostics11040585]
14. Yang P and Li N (2022) Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm. J Int Med Res, 50: 3000605221111281. [
DOI:10.1177/03000605221111281]
15. Qiu J, Cheng Z, Jiang Z, et al. (2024) Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment. Int J Mol Sci, 25 (10): 5490. [
DOI:10.3390/ijms25105490]
16. Venkatesulu BP and Krishnan S (2018) Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination. Hepatology, 67: 470-472. [
DOI:10.1002/hep.29526]
17. Ke Q, Su X, Zhou S, et al. (2011) Efficacy analysis of ultrasound-guided high-intensity focused ultrasound combined with 3D conformal radiotherapy for the treatment of primary liver cancer. Practical Journal of Cancer, 26: 184-187.
18. Ding L, Zhang Z, Jiang G (2016) Short- and long-term efficacy of ultrasound-guided radiofrequency ablation combined with conformal radiotherapy for liver cancer. Modern Oncology, 24(01): 88-91.
19. Li T (2014) Efficacy analysis of high-intensity focused ultrasound combined with 3D conformal radiotherapy for the treatment of primary liver cancer. Chinese Community Physicians, 30(17): 67-69.
20. Wang L, Li L, Wang X, et al. (2018) Comparison of combination stereotactic body radiotherapy plus high-intensity focused ultrasound ablation versus stereotactic body radiotherapy alone for massive hepatocellular carcinoma. Medical Science Monitor, 24: 8298-8305. [
DOI:10.12659/MSM.910735]
21. Zhou L, Du T, Zhu X (2015) Clinical study of high-intensity focused ultrasound combined with intensity-modulated radiotherapy for the treatment of advanced liver cancer. Journal of Difficult and Complicated Diseases, 14: 1255-1258.
22. Fujita N, Kanogawa N, Makishima H, et al. (2022) Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma. Hepatology Research, 52: 1060-1071. [
DOI:10.1111/hepr.13827]
23. Yang K, Lee JE, Park W, et al. (2023) Recent trends in radiotherapy use for major cancers in Korea. Jpn J Clin Oncol 53, 1177-1182. [
DOI:10.1093/jjco/hyad106]
24. Loi M, Comito T, Franzese C et al. (2021) Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. J Cancer Res Clin Oncol, 147: 927-936. [
DOI:10.1007/s00432-020-03389-2]
25. Gharzai LA, Wang C, Tang M, et al. (2023) Efficacy of a Second course of radiation for patients with metachronous hepatocellular carcinoma. Practical Radiation Oncology, 13: e504-e514. [
DOI:10.1016/j.prro.2023.05.008]
26. Hayashi K, Suzuki O, Wakisaka Y, et al. (2024) Prognostic analysis of radiation-induced liver damage following carbon-ion radiotherapy for hepatocellular carcinoma. Radiation Oncology, 19: 51. [
DOI:10.1186/s13014-024-02444-3]
27. Xu Z, Hu Y, Huang L (2024) Effectiveness and safety of radiofrequency ablation versus liver resection in the treatment of early-stage hepatocellular carcinoma: A systematic review and meta-analysis. Annali Italiani di Chirurgia, 95: 109-118. [
DOI:10.62713/aic.3155]
28. Li LQ, Su TS, Wu QY, et al. (2023) Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions - A Systematic Review and Network Meta-analysis. Clinical oncology (Royal College of Radiologists (Great Britain)) 35, 652-664. [
DOI:10.1016/j.clon.2023.07.002]
29. Yang GY, He ZW, Tang YC et al. (2024) Unraveling the efficacy network: A network meta-analysis of adjuvant external beam radiation therapy methods after hepatectomy. World Journal of Gastrointestinal Surgery, 16: 205-214. [
DOI:10.4240/wjgs.v16.i1.205]
30. Li J, Zhu C, Yue P, et al. (2021) Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets. Cancer Cell Int, 21: 128. [
DOI:10.1186/s12935-021-01809-y]
31. Terzi E, Golfieri R, Piscaglia F, et al. (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J Hepatol, 57: 1258-1267. [
DOI:10.1016/j.jhep.2012.07.025]
32. Wang X, Chen M, Wei R, et al. (2019) External radiation versus internal radiation for patients with advanced unresectable HCC -A SEER based study. Journal of Cancer, 10: 1171-1180. [
DOI:10.7150/jca.28983]
33. Otgontuya A, Jeng CJ, Wu TN, et al. (2023) Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis. Taiwanese Journal of Obstetrics & Gynecology, 62: 226-238. [
DOI:10.1016/j.tjog.2022.11.009]
34. Mee SF, Polan DF, Dewaraja YK, et al. (2023) Stereotactic body radiation therapy (SBRT) following Yttrium-90 ((90)Y) selective internal radiation therapy (SIRT): a feasibility planning study using (90)Y delivered dose. Phys Med Biol, 68(6): 065003. [
DOI:10.1088/1361-6560/acbbb5]
35. Koonce NA, Chen X, Moros EG, et al. (2015) PET and MRI-guided focused ultrasound surgery for hypoxic-tissue ablation combined with radiotherapy in solid tumor. International Journal of Radiation Research, 13: 1-12.